Helsinki, Finland

Suvi Koskela

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Amplidiag Oy. Active years: 2017.


% Patents Active = 100.0


 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Suvi Koskela: Innovator in Bacterial Resistance Detection

Introduction

Suvi Koskela is a prominent inventor based in Helsinki, Finland. She has made significant contributions to the field of microbiology, particularly in the detection of antibiotic resistance in bacteria. Her innovative work has implications for public health and the treatment of bacterial infections.

Latest Patents

Koskela holds a patent for a "Method and kit for detecting carbapenemase genes." This invention relates to a method and kit designed to detect carbapenemase resistance genes that cause carbapenem resistance in bacteria. The invention provides oligonucleotide primers that can be utilized in the detection process. The method is capable of detecting various resistance genes, including OXA-48, SME, GIM-1, VIM 1-22, SPM, GES 1-10, KPC 1-7, IMI 1-3/NMC-A, IMP 1-24, and several others within a single reaction.

Career Highlights

Koskela is associated with Amplidiag Oy, a company focused on developing diagnostic solutions for infectious diseases. Her work at Amplidiag Oy has been instrumental in advancing the detection of antibiotic resistance, which is a growing concern in the medical community.

Collaborations

Koskela collaborates with Juha Kirveskari, who is also involved in the field of microbiology. Their partnership enhances the research and development efforts at Amplidiag Oy, contributing to innovative solutions in bacterial resistance detection.

Conclusion

Suvi Koskela's contributions to the field of microbiology through her patent and work at Amplidiag Oy highlight her role as an innovator in the detection of antibiotic resistance. Her efforts are crucial in addressing the challenges posed by resistant bacterial strains.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…